Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): Quantitative measures for selectivity ratios obtained by screening assays

Journal of Biomolecular Screening

Volumn 17, Issue 7, 2012, Pages 857-867

  Goedken, Eric R ^a   Devanarayan, Viswanath ^a   Harris, Christopher M ^a   Dowding, Lori A ^a   Jakway, James P ^a   Voss, Jeffrey W ^a   Wishart, Neil ^a   Jordan, David C ^a   Talanian, Robert V ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

cell based assays; enzyme assays or enzyme kinetics; kinases; statistical analyses; structure activity relationships

Indexed keywords

JANUS KINASE INHIBITOR;

ARTICLE; ASSAY; CONFIDENCE IN RATIO OF SELECTIVITY RATIO; DECISION MAKING; DRUG POTENCY; MINIMUM SIGNIFICANT RATIO OF SELECTIVITY RATIO; MOLECULE; PARAMETERS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

CELL PHYSIOLOGICAL PHENOMENA; DATA INTERPRETATION, STATISTICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; JANUS KINASES; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863852551     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112447108     Document Type: Article

References (16)

1. Taylor J. An Introduction to Error Analysis: The Study of Uncertainties in Physical Measurements. University Science Books: Herndon, VA ; 1997:
2. Ghoreschi K., Laurence A., O'Shea J. J.. Selectivity and Therapeutic Inhibition of Kinases: To Be or Not To Be?. Nat. Immunol. 2009 ; 10: 356-360
3. Sorbera L. A., Serradell N., Bolós J., Rosa E., Bozzo J.. CP-690550. Drugs Future. 2007 ; 32: 674-680
4. West K.. CP-690550, a JAK3 Inhibitor as an Immunosuppressant for the Treatment of Rheumatoid Arthritis, Transplant Rejection, Psoriasis and Other Immune-Mediated Disorders. Curr. Opin. Investig. Drugs. 2009 ; 10: 491-504
5. Fleischmann R., Cutolo M., Genovese M. C., Lee E. B., Kanik K. S., Sadis S., Connell C. A., Gruben D., Krishnaswami S., Wallenstein G., Wilkinson B. E., Zwillich S. H.. Phase 2B Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) or Adalimumab Monotherapy versus Placebo in Patients with Active Rheumatoid Arthritis with an Inadequate Response to DMARDs. Arthritis Rheum. 2012 ; 64: 617-629
6. Garber K.. Pfizer's JAK Inhibitor Sails through Phase 3 in Rheumatoid Arthritis. Nat. Biotechnol. 2011 ; 29: 467-468
7. Ghoreschi K., Jesson M. I., Li X., Lee J. L., Ghosh S., Alsup J. W., Warner J. D., Tanaka M., Steward-Tharp S. M., Gadina M., Thomas C. J., Minnerly J. C., Storer C. E., LaBranche T. P., Radi Z. A., Dowty M. E., Head R. D., Meyer D. M., Kishore N., O'Shea J. J.. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). J. Immunol. 2011 ; 186: 4234-4243
8. Kremer J. M., Cohen S., Wilkinson B. E., Connell C. A., French J. L., Gomez-Reino J., Gruben D., Kanik K. S., Krishnaswami S., Pascual-Ramos V., Wallenstein G., Zwillich S. H.. A Phase 2B Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) versus Placebo in Combination with Background Methotrexate in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Alone. Arthritis Rheum. 2012 ; 64: 970-981
9. Tanaka Y., Suzuki M., Nakamura H., Toyoizumi S., Zwillich S. H.. Phase II Study of Tofacitinib (CP-690,550) Combined with Methotrexate in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Care Res. (Hoboken). 2011 ; 63: 1150-1158
10. Lacombe C., Mayeux P.. Biology of Erythropoietin. Haematologica. 1998 ; 83: 724-732 (Pubitemid 28492155)
11. Witthuhn B. A., Quelle F. W., Silvennoinen O., Yi T., Tang B., Miura O., Ihle J. N.. JAK2 Associates with the Erythropoietin Receptor and Is Tyrosine Phosphorylated and Activated following Stimulation with Erythropoietin. Cell. 1993 ; 74: 227-236 (Pubitemid 23221699)
12. Fisher J. W.. Erythropoietin: Physiologic and Pharmacologic Aspects. Proc. Soc. Exp. Biol. Med. 1997 ; 216: 358-369
13. Vijayakrishnan L., Venkataramanan R., Gulati P.. Treating Inflammation with the Janus Kinase Inhibitor CP-690,550. Trends Pharmacol. Sci. 2011 ; 32: 25-34
14. Eastwood B. J., Farmen M. W., Iversen P. W., Craft T. J., Smallwood J. K., Garbison K. E., Delapp N. W., Smith G. F.. The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies. J. Biomol. Screen. 2006 ; 11: 253-261
15. DevanarayanV.SittampalamG. S.Fit-for-Purpose Evaluation of In-Vitro Screening Assays in Drug Discovery. Drug Discovery2011. http://www. touchhealthsciences.com/articles/fit-purpose-evaluation-vitro-screening-assays- drug-discovery
16. National Institutes of Health. Assay Guidance Manual. http://assay.nih.gov/assay/index.php/Table-of-Contents.